Results 91 to 100 of about 57,323 (255)

Therapeutic Dose Response of Acoustic Cluster Therapy in Combination With Irinotecan for the Treatment of Human Colon Cancer in Mice

Frontiers in Pharmacology, 2019
Introduction: Acoustic Cluster Therapy (ACT) comprises coadministration of a formulation containing microbubble-microdroplet clusters (PS101) together with a regular medicinal drug and local ultrasound (US) insonation of the targeted pathological tissue.
Nigel Bush, Andrew Healey, Anant Shah, Gary Box, Vladimir Kirkin, Spiros Kotopoulis, Svein Kvåle, Per Christian Sontum, Jeffrey Bamber   +8 more
doaj   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

Evaluation of pomegranate rind (Punica granatum) hydroethanolic extract on blood parameters in male mice treated by Irinotecan Hcl

Armaghane Danesh Bimonthly Journal, 2015
Background & aim: Irinotecan Hcl is the first order drug for some neoplasm treatment in patients. Irinotecan Hcl has side effects on blood such as anemia and leukopeny.
N Mirazi, Sh Nosrati, A Hosseini
doaj  

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance

, 2020
Aims. We here investigated whether the combination of simvastatin and irinotecan could induce the synergistic effect on colon cancer cells with or without resistance to irinotecan. Methods. We investigated cell proliferation assay and assessed cell death
Hyun Joo Jang, Juah Jang, Eun Mi Hong, Hyun Woo Byun, Sea Hyub Kae, Se Woo Park, Jung Eun Choi, Jin Lee, Min Ho Choi, Dong Hee Koh   +9 more
core  

Genotype‐Informed Whole‐Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC

Cancer Science, EarlyView.
Overview of experimental workflow and key findings. Clinically prevalent 2‐hit and 3‐hit PDAC genotypes were first modeled in Drosophila to enable kinome‐wide genetic screening. Candidate therapeutic targets were prioritized using human tumor expression data and pathway enrichment analyses.
Han Hai, Takako Ooshio, Hui Jiang, Taku Kimura, Yusuke Satoh, Soichiro Hata, Taiga Hirata, Jiayi Liu, Tongwei Liu, Ryodai Yamamura, Masahiro Sonoshita   +10 more
wiley   +1 more source

Eruptive Acral Melanocytic Lesions Associated With Capecitabine

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Eruptive nevi and lentigines have been reported to occur in the setting of immunosuppression, which may be medication‐induced. The associated histopathologic findings have not been well described in the literature. Herein, we report the case of a woman in her 60s who had been receiving chemotherapy treatment with capecitabine, a prodrug of 5 ...
Madison Smith, Annie Jin, Jonathan A. Miles, Rosalie Elenitsas, Danielle M. DeHoratius, Emily Y. Chu   +5 more
wiley   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Optimization of irinotecan chronotherapy with P-glycoprotein inhibition

, 2014
The relevance of P-glycoprotein (P-gp) for irinotecan chronopharmacology was investigated in female B6D2F1 mice. A three-fold 24 h change in the mRNA expression of Abcb1b was demonstrated in ileum mucosa, with a maximum at Zeitgeber Time (ZT) 15 (p < 0 ...
VAN DER HORST, Gijsbertus T. J., Levi, Francis, van der Horst, Gijsbertus T. J., Okyar, Alper, Filipski, Elisabeth, Berland, Elodie, Ozturk, Narin, Guettier, Catherine, Lévi, Francis A.   +8 more
core   +2 more sources

Irinotecan in combination with new agents [PDF]

, 2004
Today, irinotecan in combination with bolus and/or infusional 5-FU/FA constitutes a standard first-line treatment for patients with metastatic colorectal cancer. In an attempt to further improve clinical outcome, the use of irinotecan in combination with
JL Van Laethem, U. Vanhofer, Sobrero, Alberto, A. Munoz, Borner, M, Van Laethem, Jean-Luc, Muñoz, A., Borner, Markus, Rougier, Philippe, P. Rougier, M. Borner, Vanhoefer, U, Van Laethem, J.-L, Vanhoefer, Udo, Rougier, P, Muñoz, A, Sobrero, A   +16 more
core   +1 more source